Topics

Gilead, Glympse Bio to explore biomarker use in NASH

07:50 EDT 29 Oct 2019 | PharmaTimes

NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function.

Original Article: Gilead, Glympse Bio to explore biomarker use in NASH

NEXT ARTICLE

More From BioPortfolio on "Gilead, Glympse Bio to explore biomarker use in NASH"

Quick Search

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...